Takeda Pharmaceutical Company Limited (TAK) has reaffirmed its fiscal year 2023 guidance, maintaining its forecast unchanged from October 2023. The company expects revenue to be JPY 3.98 trillion and core earnings per share (EPS) to be JPY 447. The guidance also indicates a low-single-digit percentage decline in core revenue and a low-20s percentage decline in core EPS. Takeda anticipates a reported operating profit of JPY 225 billion, a reported net profit of JPY 93 billion, and a free cash flow between JPY 400-500 billion. The annual dividend per share is projected to be JPY 188.